Global Blood Culture Tests Market Driven by Growing Demand for Rapid Diagnostic Techniques

By LabMedica International staff writers
Posted on 08 Aug 2023

Image: The global blood culture tests market is poised to reach USD 7.6 billion by 2028 (Photo courtesy of Freepik)

The global blood culture tests market is anticipated to grow at an 8% CAGR, rising from USD 5.2 billion in 2023 to USD 7.6 billion by 2028. The key factors fueling this market growth include the surging demand for rapid diagnostics, rising sepsis cases and their associated treatment costs, widespread infectious diseases, an aging population, and increasing incidents of bloodstream infections. However, hurdles such as the high cost of automation and a dearth of skilled laboratory personnel could limit market growth.

These are the recent findings of the global market research firm MarketsandMarkets (Northbrook, IL, USA)

In the foreseeable future, the blood culture tests market is strongly positioned for notable advancements on the back of cutting-edge technologies and pioneering research. The increased focus on personalized medicine and rapid diagnostic solutions will lead to a transformative shift in blood culture tests towards faster, more accurate, and comprehensive detection of infectious agents. There will be a surge in the prevalence of microfluidic-based platforms, enabling higher-throughput analysis and quicker processing times—critical for the early detection and efficient management of infections.

Additionally, advancements in machine learning algorithms and artificial intelligence will expedite the real-time analysis of vast datasets, enhancing the identification of pathogens and the profiling of antibiotic resistance. Moreover, the integration of point-of-care blood culture devices with telemedicine and cloud-based platforms will improve accessibility and facilitate smooth communication between medical professionals and patients. As the growth of the blood culture tests market surges, these advancements will play a key role in revolutionizing the diagnosis and treatment of infectious diseases, ultimately resulting in improved patient outcomes and global healthcare systems.

Based on method, the automated blood culture segment is projected to exhibit the highest growth during the forecast period due to its rapid turnaround time and reduced contamination risk owing to low manual intervention. On the basis of product, the consumables segment not only holds the largest market share but is also poised for recording the highest growth in the blood culture tests market. This can be attributed to the frequent acquisition of media for bacteria, fungi, and yeast detection, coupled with the rise in drug-resistant infections like methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria.

Based on technology, the molecular technologies segment is expected to witness the highest growth during the forecast period, driven by the rising prevalence of sepsis. This condition necessitates rapid diagnostic methods for detecting fungi, bacteria, and mycobacteria in blood samples. On the basis of application, the bacteremia segment is set to exhibit the highest growth during the forecast period due to the increasing instances of bloodstream infections and the global surge in sepsis cases.

Based on end user, the hospital laboratories segment holds the largest market share in the blood culture tests market, primarily due to the rising number of sepsis cases in emergency departments where it is most frequently encountered. Geographically, the Asia-Pacific blood culture tests market is poised to witness the highest growth during the forecast period. This can be attributed to the high prevalence of sepsis, government initiatives to bolster awareness, growing demand for effective diagnostic methods, and an increase in regulatory approvals and availability of blood culture test products in the region.

Related Links:
MarketsandMarkets